Gilead’s Remdesivir reduces Covid-19 mortality risk – company

RIO DE JANEIRO, BRAZIL – Gilead Sciences Inc. said an analysis showed its antiviral Remdesivir reduced mortality in patients hospitalized with Covid-19 and increased the likelihood of discharge on day 28 after a five-day course of treatment.

The drugmaker said Monday that it analyzed data on 98,654 patients from three retrospective studies of actual treatment in patients hospitalized with Covid-19.

Remdesivir achieved statistically significant reductions in the risk of death of 54% and 23%, respectively, among patients analyzed in two of the studies, the company said. The data were presented this week at the World Microbe Forum (WMF).

According to Gilead, the results were observed consistently at different time points during the pandemic and in different regions.

Remdesivir is approved in the U.S., India and South Korea for emergency use in critically ill patients and has received full approval in Japan.

Related coverage: Rabobank revises Brazilian coffee crop upward after finding higher stocks · Brazilian soybean exports in June slow down pace and are below 2020 – Secex · U.S. to donate more than 14 million vaccine doses to Latin America and Caribbean · Brazil's Health Minister announces delivery of 1.5 million Janssen vaccine doses to Brazil on Tuesday

More: Brazil news in English, every day from The Rio Times.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief